June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Atropine’s inhibition of experimental myopia in chickens can be disrupted by serotonergic stimulation
Author Affiliations & Notes
  • Kate Thomson
    Center for Research into Therapeutic Solutions, University of Canberra, Bruce, Australian Capital Territory, Australia
  • Cindy Karouta
    Center for Research into Therapeutic Solutions, University of Canberra, Bruce, Australian Capital Territory, Australia
  • Regan Scott Ashby
    Center for Research into Therapeutic Solutions, University of Canberra, Bruce, Australian Capital Territory, Australia
    Research School of Biology, Australian National University, Australian Capital Territory, Australia
  • Footnotes
    Commercial Relationships   Kate Thomson, None; Cindy Karouta, None; Regan Ashby, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 3397. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kate Thomson, Cindy Karouta, Regan Scott Ashby; Atropine’s inhibition of experimental myopia in chickens can be disrupted by serotonergic stimulation. Invest. Ophthalmol. Vis. Sci. 2020;61(7):3397.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Atropine is classified as a muscarinic-cholinergic (mAChR) antagonist. However, it is unclear if this is the receptor family by which it exerts its anti-myopia effects. In addition to mAChRs, there are a number of candidate receptor systems within the retina which atropine may instead target, including that of serotonergic receptors. Therefore, this study investigated whether atropine’s protective effects against the development of form-deprivation myopia (FDM) can be disrupted by co-administration with the mAChR agonist muscarine, serotonin, or the serotonergic agonist 5-methoxytryptamine (5-MOT).

Methods : Chicks were divided between 9 groups (n=6 per group) and treated for 4 days: 1) age-matched untreated controls, 2) FDM only, 3) FDM plus 0.015mM atropine, 4) FDM plus 0.015mM atropine and 0.06mM muscarine, 5) FDM plus 0.015mM atropine and 0.6mM muscarine 6) FDM plus 0.015mM atropine and 0.05mM serotonin, 7) FDM plus 0.015mM atropine and 0.5mM serotonin, 8) FDM plus 0.015mM atropine and 0.05mM 5-MOT, and 9) FDM 0.015mM atropine and 0.5mM 5-MOT. For each drug treatment, a 10µL injection was made into the vitreous chamber once daily at 9am (lights on).

Results : After 4 days of treatment, chicks administered atropine alone were significantly protected against the myopic refractive shift associated with FDM (FDM: -1.6±0.2D, FDM atropine: -0.2±0.4D, p<0.05). This protective effect was not inhibited by the co-administration of the mAChR agonist muscarine (0.06mM: 1.65±0.3D, p<0.001; 0.6mM: 0.5±0.3D, p<0.001), but was by co-administration of serotonin (0.05mM: -0.9±0.3D, p=0.181; 0.5mM: -1.0±0.4D, p=0.500) or the serotonergic agonist 5-MOT (0.05mM: -0.4±0.4D, p=0.266; 0.5mM: -1.1±0.5D, p=0.764). This same effect was observed in axial length measurements, with the protection afforded by atropine (FDM: 9.06±0.05mm, FDM atropine: 8.84±0.5mm, p<0.001) inhibited by both serotonin (0.05mM: 9.05±0.05mm, p=0.210; 0.5mM: 9.02±0.06mm, p=0.167) and 5-MOT (0.05mM: 8.94±0.05mm, p=0.198; 0.5mM: 8.98±0.05mm, p=0.584), but not by muscarine (0.06mM: 8.60±0.06mm, p<0.001; 0.6mM: 8.67±0.06mm, p<0.001).

Conclusions : Unlike muscarine, both serotonergic agents significantly disrupted atropine’s protection against the development of FDM, suggesting that atropine may elicit its anti-myopia effects through the inhibition of serotonergic receptors, rather than mAChRs.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×